Ouch, That's Gotta Hurt!

Recs

1

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

It's one thing to get beaten in a head-to-head clinical trial by a rival drug, like Johnson & Johnson (NYSE: JNJ) did to Amgen (Nasdaq: AMGN) and Wyeth (NYSE: WYE) last week. It's another to get trounced by alternative medicine.

But that's what happened to Wyeth this week, as researchers announced results of a clinical trial pitting Effexor against acupuncture to see which could relieve hot flashes in women after breast cancer treatment. In the small study (47 women participated), acupuncture was just as effective as Effexor in getting rid of the symptoms, but its effect lasted for 15 weeks after treatment, compared to just two weeks for Effexor. There were also fewer side effects associated with the acupuncture treatment than with Effexor. That's got to sting a little. (Sorry.)

Of course, there's a bit of a caveat here. In a "normal" study, the patients don't know whether they're receiving the drug or a placebo. In this one, well, it's kind of hard to disguise the fact that they're receiving acupuncture. Still, the results are impressive.

Nonetheless, the findings shouldn't hurt Wyeth's revenue too much. Effexor sales mostly stem from patients treating depression, not hot flashes. And besides, I imagine that very few doctors will send their patients out to the acupuncturist, rather than writing a prescription for Effexor, GlaxoSmithKline's (NYSE: GSK) Paxil, or Eli Lilly's (NYSE: LLY) Prozac, all anti-depressants used to treat hot flashes in post-breast cancer women. (More traditional hormone therapy could raise the risk of the cancer returning.) That's just not the way doctors think, positive clinical trial or not.

Wyeth also has bigger problems than getting beat in a head-to-head trial by a bunch of needles. Effexor XR -- its extended-release drug -- will eventually face generic competition, so Wyeth is desperately trying to switch patients to its me-too drug, Pristiq. Add to that Teva Pharmaceuticals' (Nasdaq: TEVA) attempt to stab Wyeth in the heart by launching a generic version of its heartburn medication, Protonix, and those little needles look small by comparison.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Eli Lilly, Johnson & Johnson, and Glaxo are all Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 22, 2008, at 6:00 PM, kpness wrote:

    Who would going to sponsor acupuncture studies if there's no money to be made? Maybe insurers should begin accepting acupuncture as viable treatments.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 733760, ~/Articles/ArticleHandler.aspx, 11/10/2009 4:02:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:02 PM
GSK $41.37 Up +0.85 +2.10%
GlaxoSmithKline pl… CAPS Rating: *****
JNJ $60.75 Up +0.45 +0.75%
Johnson & Johnson CAPS Rating: *****
LLY $35.32 Up +0.82 +2.38%
Eli Lilly & Co. CAPS Rating: ****
WYE $50.39 Down +0.00 +0.00%
Wyeth CAPS Rating: ***
AMGN $54.91 Up +0.22 +0.40%
Amgen, Inc. CAPS Rating: ****
TEVA $53.20 Up +1.17 +2.25%
Teva Pharmaceutica… CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Chief Financial Officer: A Chief Financial Officer aka CFO is a corporate officer, often of a public company, whose primary responsibility is the management of financial risks for said company.

Want to learn more or edit this definition?
Click here to read more!